No Data
【Brokerage Focus】BOCOM INTL points out that Innovative Drugs companies continue the trend of going abroad, and is bullish on the Sector, which still has significant room for recovery.
Jinwu Finance | BOCOM INTL stated that in the new year, Chinese Innovative Drugs companies continue the trend of going abroad. INNOVENT BIO (01801), SIMCERE PHARMA (02096), Kangnuo Ya (02162), Kelun Botai (06990) / HeBo Pharma (02142), Ying'en Bio and other companies successfully licensed their Innovative Drug Assets through MNC big pharma or through NewCo format. The bank believes that going abroad will remain one of the biggest highlights of the Innovative Drugs Sector in 2025, and more significant Trades are worth looking forward to. In combination with previous drug and medical equipment procurement continuously creating funding space for medical insurance payments of innovative varieties, subsequent finance and medical insurance/business.
Zhitong Hong Kong Stock Shareholder Equity Disclosure | January 13
Disclosure of Shareholder equity in Hong Kong stocks | January 13
Everest Medicines Clarifies Unusual Price, Trading Volume Movements
Cloud Top Nova (01952.HK) is operating well, and CEO Luo Yongqing along with the management has not engaged in any sale or Shareholding of company shares.
The CEO, Luo Yongqing, and the management team of Cloud Top Xinyao have not engaged in any sale or reduction of company shares, the company's operation is in good condition, and there are no negative news. The management and major Shareholders are full of confidence in the company's development. The interest from internationally renowned investment Institutions has prompted Kangqiao Capital to timely sell some of their holdings. Due to the high demand from these well-known investment Institutions, the Trade was achieved through bulk trading with Kangqiao Capital. After this bulk trade, Kangqiao Capital will still Hold over 34% of the shares, demonstrating its firm confidence. We believe this transaction will further broaden our international investor base and enhance the stock price.
The Hang Seng Index fluctuates around the 20,000-point mark, and short-term new stocks are seeing a return of profit-making effects ｜ A barometer of Hong Kong stocks.
① The Hang Seng Index is fluctuating around the 20,000 point mark, what hot topics is the market focusing on? ② The return of short-term new stock profitability effects, what impact does it have?
The Medical Care Sector is improving, with KJ Pharma (02171) rising over 18%. Institutions indicate that there is hope for entering a new growth cycle by 2025.
Jinwu Finance News | The Medical Care Sector is favorable, with the Hang Seng Healthcare Index rising 0.91% today, reporting 2338.61 points. Keji Pharmaceuticals (02171) rose over 18%, WUXI APPTEC (02359) rose 5.01%, Genting New Vision (01952) rose 4.02%, and PHARMARON (03759) rose 3.94%. Guosen Securities pointed out that domestic medical demand continues to upgrade, and the macro economy is expected to gradually improve. Currently, the Industry is undergoing considerable supply-side structural reforms, and centralized procurement for Pharmaceuticals and Medical Devices is nearing completion, with the potential to enter a new growth cycle in 2025. Geopolitical disturbances are affecting...
Press Release: Everest Medicines Strengthens Management Team With Appointments of Chief Medical Officer and Chief Product Officer
